Get the Stockscreener App
1.41
2.17%
0.03
Opko Health Inc stock is traded at $1.41, with a volume of 3.64M.
It is up +2.17% in the last 24 hours and up +2.17% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
See More
Previous Close:
$1.38
Open:
$1.39
24h Volume:
3.64M
Relative Volume:
1.28
Market Cap:
$1.12B
Revenue:
$711.41M
Net Income/Loss:
$-133.73M
P/E Ratio:
-7.4211
EPS:
-0.19
Net Cash Flow:
$-199.99M
1W Performance:
+2.92%
1M Performance:
+2.17%
6M Performance:
-16.07%
1Y Performance:
-12.42%
1-Day Range:
$1.38
$1.42
1-Week Range:
$1.35
$1.42
52-Week Range:
$1.11
$2.035
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.41 | 1.11B | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-25 | Initiated | JP Morgan | Neutral |
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
Tejara Capital Ltd Has $1.43 Million Position in OPKO Health, Inc. $OPK - MarketBeat
Using portfolio simulators with OPKO Health Inc. includedJuly 2025 Momentum & Daily Chart Pattern Signals - Newser
What earnings revisions data tells us about OPKO Health Inc.Chart Signals & Verified Short-Term Plans - Newser
Does OPKO Health Inc. qualify in momentum factor screeningJuly 2025 Sentiment & Free Risk Controlled Daily Trade Plans - Newser
Can OPKO Health Inc. deliver alphaJuly 2025 Summary & AI Driven Price Forecasts - thegnnews.com
OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics - Yahoo Finance
How high can OPKO Health Inc. stock price go in 20252025 Top Gainers & Technical Confirmation Trade Alerts - Newser
Price momentum metrics for OPKO Health Inc. explained2025 Stock Rankings & Daily Momentum Trading Reports - Newser
How OPKO Health Inc. stock performs during market volatilityJuly 2025 Setups & Stepwise Swing Trade Plans - sundaytimes.kr
Market reaction to OPKO Health Inc.’s recent newsQuarterly Profit Review & Long-Term Growth Stock Strategies - Newser
Tools to monitor OPKO Health Inc. recovery probabilityWeekly Trade Report & Low Risk Investment Opportunities - Newser
OPKO Health Inc. Company’s Quarterly Earnings Growth: What the Numbers SayGap Up & Breakout Confirmation Trade Signals - Newser
Phillip Md Et Al Frost Purchases 675,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock - MarketBeat
OPKO Health (NASDAQ:OPK) Shares Gap Up Following Insider Buying Activity - MarketBeat
OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) - MSN
Y.D. More Investments Ltd Has $2.97 Million Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Is OPKO Health Inc. affected by consumer sentimentBreakout Stocks with Huge Upside - newsyoung.net
Phillip Frost Spends US$891k On OPKO Health Stock - simplywall.st
Phillip Frost Buys Handful Of Shares In OPKO Health - Yahoo Finance
OPKO Health Q3 EPS Estimate Reduced by Barrington Research - MarketBeat
Phillip Frost's Significant Investment in Opko Health: A Bold Move - AInvest
Opko Health’s CEO Makes a Bold Move with Massive Stock Purchase! - TipRanks
Quote - OPKO Health, Inc.
Entera Bio Beats Q2 EPS Estimates - The Motley Fool
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Opko Health (OPK) Q2 Revenue Falls 14% - AOL.com
OPKO Health (OPK) Q2 2025 Earnings Call Transcript - AOL.com
Barrington Research Forecasts Lower Earnings for OPKO Health - Defense World
Brokerages Set OPKO Health, Inc. (NASDAQ:OPK) Price Target at $2.75 - MarketBeat
OPKO Health (NASDAQ:OPK) Sets New 52-Week Low on Disappointing Earnings - MarketBeat
Analyzing drawdowns of OPKO Health Inc. with statistical toolsChart Risk Profile for Capital Preservation - Newser
Acromegaly Pipeline 2025: Key Companies, MOA, ROA, and Clinical - openPR.com
Opko Health (OPK) Reports Fiscal Q2 2025 Results - Insider Monkey
Optimistic Growth Prospects for OPKO Health: Buy Rating with 89% Upside Potential - TipRanks
Can OPKO Health Inc. Outperform Peers After Recent PullbackAccurate Technical Trend Reversal Picks Detected - metal.it
What analysts say about OPKO Health Inc. stockFree Stock Index Interpretation - Jammu Links News
What is the dividend policy of OPKO Health Inc. stockInvest confidently with data-backed picks - Jammu Links News
OPKO Health Inc. Stock Analysis and ForecastUnrivaled growth potential - Jammu Links News
What drives OPKO Health Inc. stock priceBuild wealth steadily with smart stock selection - Jammu Links News
What makes OPKO Health Inc. stock price move sharplyOutstanding investment returns - Jammu Links News
What is OPKO Health Inc. company’s growth strategyMaximize gains with professional stock picks - Jammu Links News
What are the latest earnings results for OPKO Health Inc.Achieve breakthrough performance with smart picks - Jammu Links News
Is OPKO Health Inc. a growth stock or a value stockUnlock exclusive stock market forecasts - Jammu Links News
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opko Health Inc Stock (OPK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 10 '25 |
Buy |
1.36 |
125,000 |
169,712 |
214,001,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 08 '25 |
Buy |
1.48 |
125,000 |
184,650 |
213,876,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 01 '25 |
Buy |
1.65 |
100,000 |
164,850 |
213,751,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 28 '25 |
Buy |
1.70 |
150,000 |
254,385 |
213,651,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 17 '25 |
Buy |
1.74 |
200,000 |
347,820 |
213,501,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Feb 28 '25 |
Buy |
1.71 |
67,434 |
115,312 |
213,301,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 28 '25 |
Buy |
1.47 |
47,537 |
70,060 |
213,234,014 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 17 '25 |
Buy |
1.47 |
150,000 |
220,425 |
213,186,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 15 '25 |
Buy |
1.48 |
500,000 |
740,850 |
213,036,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 13 '24 |
Buy |
1.59 |
125,000 |
199,375 |
212,536,477 |
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):